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Glycerophosphoinositols (GPIs) are bioactive, diffusible phosphoinositide metabolites of
phospholipase A2 that act both intracellularly and in a paracrine fashion following their
uptake by specific transporters.The most representative compound, glycerophosphoinos-
itol (GroPIns), is a ubiquitous component of eukaryotic cells that participates in central
processes, including cell proliferation and survival. Moreover, glycerophosphoinositol 4-
phosphate (GroPIns4P ) controls actin dynamics in several cell systems by regulating Rho
GTPases. Recently, immune cells have emerged as targets of the biological activities of
the GPIs. We have shown that exogenous GroPIns4P enhances CXCL12-induced T-cell
chemotaxis through activation of the kinase Lck in a cAMP/PKA-dependent manner. While
highlighting the potential of GroPIns4P as an immunomodulator, this finding raises ques-
tions on the role of endogenously produced GroPIns4P as well as of other GPIs in the
regulation of the adaptive immune responses under homeostatic and pathological settings.
Here we will summarize our current understanding of the biological activities of the GPIs,
with a focus on lymphocytes, highlighting open questions and potential developments in
this promising new area.
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The glycerophosphoinositols (GPIs) are ubiquitous water-soluble
phosphoinositide metabolites produced by all eukaryotic cells
(1–3). Not surprisingly considering their central role in the orches-
tration of signaling cascades, among the phosphoinositides it is
the inositol phosphates that have monopolized the scene. Accu-
mulating evidence has however highlighted a role for the GPIs
as modulators of important biological functions in a number
of cell types, including T-lymphocytes, in both physiological and
pathological settings. Here we will summarize our current under-
standing of the metabolic pathways that regulate GPI production
and discuss their biological activities, focusing on T-cells.
BIOSYNTHESIS, TRANSPORT AND DEGRADATION OF GPIs
The GPIs, which include glycerophosphoinositol (GroPIns)
and its phosphorylated derivatives glycerophosphoinositol
4-phosphate (GroPIns4P) and glycerophosphoinositol 4,5-
bisphosphate (GroPIns4,5P2), are generated from membrane
phosphoinositides through two sequential deacylation reactions
that are carried out by a phospholipase A2 (PLA2) and a lysophos-
pholipase (2). Studies on the most abundant of these metabolites,
GroPIns, have provided evidence that both of these reactions can
be catalyzed by the same enzyme, which has been identified in
thyroid cells and macrophages as the α isoform of group IV PLA2
(PLA2IVα) [(4, 5); Figure 1]. We have recently shown that the
same enzymatic pathway is responsible for GroPIns4P produc-
tion in macrophages upon treatment with a pro-inflammatory
stimulus (unpublished results; Figure 1).
Glycerophosphoinositols can interact with intracellular targets
and/or be released into the extracellular medium through specific
membrane transporters, following their chemical gradient. The
GroPIns transporter, which is responsible for the bidirectional
transfer of GroPIns, was initially identified in yeast (6), and its
human ortholog is the Glut2 permease (7). Reasonably, Glut2
represents only one of the mammalian GroPIns transporters, as
it has cell-specific expression patterns, while GroPIns membrane
permeation appears to be a general process. There is also evi-
dence of GroPIns4P membrane transport. Although no specific
transporter for GroPIns4P has been identified to date, several
GroPIns4P-mediated activities show biochemical features that
indicate specific, transporter-mediated mechanisms (8).
The half-life of GPIs is relatively short both inside the cell and in
the extracellular milieu. This applies in particular to the phospho-
rylated, biologically active derivative, GroPIns4P which is rapidly
metabolized within the cell, undergoing dephosphorylation to
GroPIns through a Ca2+-dependent and GroPIns4P-selective
activity associated with the cell membrane fraction (Figure 1).
Alternatively, a Ca2+-insensitive activity leads to the phosphory-
lation of GroPIns4P to GroPIns4,5P2 (8). GroPIns can be rea-
cylated to phosphatidylinositol (PtdIns) both in whole cells and
in membrane fractions. At variance, no detectable reacylation of
GroPIns4P has been documented to date (8).
The glycerophosphodiesterases GDE1 and GDE3, both of
which are membrane-bound ectoenzymes, catalyze the hydrolysis
of extracellular GroPIns (9, 10). GDE1 is ubiquitously expressed
and hydrolyzes GroPIns to produce inositol and glycerol phos-
phate (9). GDE1 activity is regulated by G-protein-coupled recep-
tors, and it is stimulated by β-adrenergic receptor agonists but
inhibited by α-adrenergic receptor agonists and lysophosphatidic
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FIGURE 1 | Schematic representation of the GroPIns metabolism. The
formation of GroPIns occurs from membrane phosphatidylinositol (PtdIns) via
two sequential steps, both of which are catalyzed by PLA2IVα. The first
deacylation produces lysophosphatidylinositol (LysoPtdIns) and free
arachidonic acid, since PLA2IVα selectively hydrolyzes phosphoinositides
substituted in the sn-2 position with arachidonic acid (49). The second
deacylation releases free fatty acid and GroPIns. As indicated, PLA2IVα
supports both of these deacylation steps, as demonstrated in in vitro
investigations using purified phosphoinositide and lysophosphatidylinositol
substrates together with the recombinant enzyme (4). Once produced in the
cytoplasm, GroPIns can be active on intracellular targets or can be released
through the Glut2 transporter into the extracellular space, where it can act as
a paracrine factor on nearby target cells. The subsequent catabolism of
GroPIns is instead located on the extracellular side of the plasma-membrane
and is mediated by the GDEs. GroPIns4P formation, also schematized, occurs
starting from membrane phosphatidylinositol 4-phosphate which is
hydrolyzed, as for GroPIns, by PLA2IVα (unpublished observations, see main
text for details).
acid, thus providing a further level of modulation of GroPIns
metabolism (9). GDE3 is a marker of osteoblast differentiation,
and is predominantly expressed in mature osteocytes (11). GDE3
hydrolyzes GroPIns with a different type of attack of the phospho-
diester bond, which produces inositol phosphate and glycerol (10).
GroPIns4P is not substrate of GDE1 or GDE3, but it can compete
with GroPIns for its hydrolysis by these glycerophosphodiesterases
(9, 10).
GPI PRODUCTION IN IMMUNE CELLS
GroPIns IS PRODUCED BY MACROPHAGES IN RESPONSE TO
PRO-INFLAMMATORY STIMULI
A number of pharmacological and pro-inflammatory stim-
uli have been shown to trigger phosphoinositide hydrolysis in
macrophages (2). Similar to other cell types, GroPIns produc-
tion in these cells is regulated by a Ca2+-dependent pathway
involving the PLA2-catalyzed deacylation of PtdIns (2). Studies
on macrophages treated with cholera or pertussis toxin provided
evidence that PLA2 is activated downstream of G proteins, cat-
alyzing the hydrolysis of PtdIns and leading to the production of
arachidonic acid derivatives and GroPIns (12). A similar path-
way was identified in Kupffer cells, the resident macrophages of
the liver, following stimulation with inflammatory mediators pro-
duced upon bacterial endotoxin challenge (13, 14). A concerted
activation of the arachidonate pathway and production of GroPIns
has been reported in several other cell types (2).
PLA2IVα, which had been identified as the specific, Ca2+-
dependent PLA2 responsible for GroPIns production in thyroid
cells (4), has been recently demonstrated to carry out this func-
tion also in macrophages. Zizza and colleagues (5) showed that
PLA2IVα, which is abundantly expressed in macrophages, is phos-
phorylated by the MAP kinases Erk1/2 and by the stress-activated
kinases p38 and JNK and translocates to the membrane of nascent
phagosomes during Fc-Receptor (FcR)-mediated phagocytosis. A
selective PLA2IVα activation was observed to also occur upon
LPS treatment which, similar to FcR engagement, triggers arachi-
donic acid release (5). Moreover, pharmacological inhibition
of PLA2IVα completely abolished both LPS- and phagocytosis-
mediated GroPIns production. Interestingly, a time course analy-
sis of GroPIns production during FcR-mediated phagocytosis
revealed a persistent increase in the levels of intracellular GroPIns
over time, which was paralleled by GroPIns release into the extra-
cellular medium (our unpublished observations). This suggests
that GroPIns may participate in the inflammatory responses of
macrophages by acting not only in an autocrine manner, but also
as a paracrine factor.
The intracellular levels of the GPIs have also been mea-
sured in T-cells. Mass spectrometry data showed that Jurkat
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T-cells are among the cell lines with low intracellular levels of
GroPIns (45± 1µM) (15, 16). Moreover, these basal levels are not
increased by known pharmacological activators of PLA2IVα, such
as Ca2+ ionophores, or by chemotactic stimuli, such as CXCL12,
which suggests that a Ca2+-independent enzyme is involved in
GroPIns production in these cells. Alternatively, the concentra-
tions of arachidonoyl-substituted PtdIns, the GPI precursor, may
not be sufficient to produce significant increases in the levels of
intracellular GroPIns.
MODULATION OF GroPIns PRODUCTION DURING IMMUNE CELL
DIFFERENTIATION
Phospholipase A2 activation is not only triggered by plasma-
membrane receptors but also occurs during cell differentiation
(17–19). Mountford and colleagues provided evidence that the
levels of phosphoinositides change during the differentiation of
both myeloid and lymphoid cells (20–22). Using HL60 promyelo-
cytic cells, which can differentiate either to neutrophils in response
to all-trans retinoic acid and granulocyte-colony-stimulating fac-
tor or to monocytes in response to 1α-25-dihydroxyvitamin D3,
they showed that the intracellular GroPIns levels increased in
the early stages of differentiation to either lineages, eventually
doubling in fully differentiated cells. Consistent with these find-
ings, GroPIns levels increased in neutrophils that spontaneously
differentiated in culture, as compared to the initial blasts (22).
Similar experiments, carried out on paired cell lines represen-
tative of immature and mature states of B-lymphocytes (Ba/F3
and NSI cells) and T-lymphocytes (S49 and C8166 cells) showed
substantial increases in GroPIns levels in the cells representative
of the mature states (22). Although more accurate methods to
quantitate GroPIns as well as more physiological differentiation
conditions will be required to validate these data, the changes in
the concentrations of intracellular GroPIns suggest a role for this
metabolite in the regulation of both myeloid and lymphoid cell
differentiation.
GroPIns4P PRODUCTION BY MACROPHAGES
In addition to GroPIns, its monophosphorylated derivative,
GroPIns4P, has been detected in several cell types, including
macrophages [(2); our unpublished observations)]. PLA2IVα, is
responsible for the production of both GPIs (i.e., GroPIns and
GroPIns4P), based on the relative availability of the respective
lipid precursors (PtdIns and PtdIns4P, respectively) [(4, 5); our
unpublished observations]. A conundrum in these studies are
the technical limitations in the accurate measurement of these
metabolites. For example, the relatively high levels of GroPIns
make the detection of small increases more difficult, which might
explain why increases in GroPIns4P (which generally represents
<3% of the total GPIs) do not always appear to be paralleled by
increases in GroPIns. The rapid metabolism of GroPIns4P is a
further drawback for precise determinations of its levels, although
this was partially overcome by performing GroPIns4P measure-
ments in the presence of orthovanadate, a general phosphatase
inhibitor (2), which made it possible to monitor GroPIns4P
increases in macrophages exposed to LPS (our unpublished obser-
vation). At variance with macrophages, no detectable production
of GroPIns4P can be observed in T-cells (16).
THE GPIs AS MODULATORS OF T-CELL FUNCTIONS: FACTS
AND HYPOTHESES
GroPIns4P PROMOTES ACTIN POLYMERIZATION IN T-LYMPHOCYTES
Cortical actin rearrangements, which are regulated by the Rho
family of small GTPases (23), are crucial for a number of processes
that orchestrate T-lymphocyte activation and motility (24, 25).
Exogenous administration of GroPIns4P to fibroblasts induces
the formation of actin ruffles and stress fibers by modulating the
activity of Rac and Rho (26, 27), suggesting a potential role for
this phosphoinositide derivative in the regulation of the actin
cytoskeleton in other cell types. Treatment of both Jurkat T-
cells and peripheral blood lymphocytes from healthy donors with
GroPIns4P induces indeed actin polymerization (16), suggesting
that the processes involving F-actin dynamics, including redistri-
bution of components associated with lymphocyte motility and
immune synapse assembly might be modulated by GroPIns4P.
The ability of GroPIns4P to promote actin polymerization in
T-cells stems,at least in part, from its ability to induce the phospho-
rylation of the GDP/GTP exchanger Vav (16), which controls the
activation of Rac and Cdc42 in hematopoietic cells (28). These data
are consistent with the finding that GroPIns4P triggers a signaling
cascade in fibroblasts that leads to plasma-membrane translo-
cation of Tiam1, a Rac-specific GDP/GTP exchanger in these
cells (27). This activity provides a mechanistic explanation of the
agonistic effects of GroPIns4P on the actin cytoskeleton dynamics.
The ability of GroPIns4P to promote Vav activation suggests
the possibility that it may also modulate gene expression. Vav ini-
tiates indeed a pathway involving recruitment to active Rac of the
serine/threonine kinase Pak1, which triggers the activation of p38
and JNK that directly or indirectly activate a number of transcrip-
tion factors (29). Consistent with this notion, T-cell treatment
with GroPIns4P resulted in activation of both p38 and JNK, with
a similar time course as Vav (16).
VAV ACTIVATION BY GroPIns4P REQUIRES LCK
Tyrosine phosphorylation of Vav is mediated by the cooperative
activity of Syk and Src family protein tyrosine kinases (PTKs) (28).
We have shown that treatment of T-cells with GroPIns4P results
in enhanced Lck activity [(16); Figure 2]. Although other mech-
anisms may account for Vav activation, this event is likely to be
causal to the agonistic activity of GroPIns4P on Vav activation
and the resulting actin cytoskeleton rearrangements. GroPIns4P
fails indeed to trigger Vav phosphorylation in the Lck-deficient
Jurkat T-cell variant JCaM.1 (16, 30). Moreover, GroPIns4P trig-
gers Src phosphorylation in fibroblasts, which is required for
plasma-membrane translocation of Tiam1 (27). Lck activation,
as well as Src activation, is not a direct effect of GroPIns4P, at
least as assessed in vitro (16). Unfortunately, while these studies
have restricted the field, no final mechanism of action for the GPIs
can be postulated, until a proteomic approach to identify direct
interactors can be completed.
GroPIns4P TARGETS LCK-DEPENDENT SIGNALING BY MODULATING
cAMP
In quiescent T-cells Lck is kept in an inactive state by the inhibitory
kinase Csk, which becomes phosphorylated and activated by the
cAMP-dependent serine/threonine protein kinase A (PKA) (31).
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FIGURE 2 | Convergence of signals by CXCL12 and GroPIns4P on
adenylate cyclase activity. CXCL12 binding to its cognate receptor CXCR4
leads to activation of Lck, which stably interacts with the receptor. Lck in
turn phosphorylates multiple tyrosine residues in the cytosolic tails of the
TCR/CD3 complex, thereby triggering a signaling cascade involving Vav
activation and eventually actin cytoskeletal rearrangements. Lck activity is
further potentiated by CXCR4-dependent stimulation of Gi protein which, by
inhibiting adenylate cyclase, lowers the levels of intracellular cAMP, resulting
in decreased PKA-dependent activation of Csk, a negative regulator of Lck.
GroPIns4P potentiates migratory signaling by CXCL12 by blocking the
activity of Gs protein, thereby further lowering adenylate cyclase activity
and hence the intracellular cAMP levels and contributing to Lck activation.
Phosphorylation states and events are shown as small blue circles.
Activation events are shown as arrows, inhibition events as truncated lines.
We showed that treatment of Jurkat T-cells with GroPIns4P results
in a decrease in the levels of cAMP, leading to impaired PKA acti-
vation and Csk phosphorylation. Hence the agonistic activity of
GroPIns4P on Lck activation and downstream signaling results
from its ability to inhibit cAMP production (16). These results
are consistent with the finding that GroPIns4P (but not GroPIns
or GroPIns4,5P2) inhibits adenylate cyclase activity in other cell
types (32, 33). It is noteworthy that cAMP/PKA-mediated modu-
lation of molecules downstream of Lck may also contribute to its
effects on F-actin dynamics in T-cells (34), including Rho itself,
which is phosphorylated by PKA on an inhibitory residue (35, 36).
The ability of GroPIns4P to activate Lck, which is responsi-
ble for initiation of the T-cell receptor (TCR) signaling cascade,
strongly suggests that other signaling events, in addition to the
Vav/p38/JNK pathway, might be triggered by GroPIns4P. One of
the key targets of Lck both in TCR (37) and chemokine receptor
signaling (38) is the PTK ZAP-70, which couples these receptors
to multiple signaling pathways, including the Ras/MAP kinase
pathway (39). GroPIns4P induces indeed the activation of ZAP-
70 and the adaptor Shc (16), which interacts with, and becomes
phosphorylated by ZAP-70 in response to TCR engagement and
contributes to Ras activation by recruiting the Grb2/Sos complex
(40). Consistent with its ability to promote Shc phosphoryla-
tion, GroPIns4P activates Erk1/2. These effects of GroPIns4P
are crucially dependent on Lck, as they fail to occur in JCaM.1
cells (16).
GroPIns4P ENHANCES CXCR4 SIGNALING
The ability of GroPIns4P to promote actin polymerization in
T-cells profoundly influences their responses to chemokines.
GroPIns4P (but not the other GPIs) enhances indeed CXCR4-
dependent chemotaxis toward CXCL12 (16), a chemokine that
regulates lymphocyte homing to secondary lymphoid organs
under homeostatic conditions (39). Interestingly, the two sig-
nals may converge, at least in part, on adenylate cyclase. In fact,
CXCL12-mediated activation of CXCR4 promotes the release of
the α-subunit of heterotrimeric inhibitory G protein (Gi), thereby
inhibiting adenylate cyclase activity (39). Moreover, in Jurkat T-
cells GroPIns4P reverses the cAMP-elevating activity of cholera
toxin, which ADP-ribosylates the α-subunit of stimulatory G
proteins (Gs) resulting in their persistent activation. This indi-
cates that GroPIns4P is able to decrease cAMP production and
cAMP/PKA-dependent Csk activation by inhibiting Gs. These
mechanisms can account for the additive effect of CXCL12 and
GroPIns4P on Lck activation [(16); Figure 2].
Recent evidence supports a crosstalk between the TCR and
CXCR4. The TCR is indeed transactivated by CXCR4 which then
uses the TCR machinery to elicit and potentiate downstream sig-
naling (38, 41). Similar to other G-protein-coupled receptors,
CXCR4 directly interacts with and activates Lck. The association
of CXCR4 with the TCR at the cell surface allows Lck to localize
in close contact with the intracellular domains of the TCR/CD3
complex and phosphorylate CD3ζ, thereby triggering downstream
signaling (39). By promoting Lck activation GroPIns4P might
potentiate the ability of CXCR4 to transactivate the TCR and
hence enhance the signaling cascades leading to T-cell chemotaxis,
including the pathway leading to the Lck-dependent recruitment
of Shc to the CXCR4/TCR dimer.
GroPIns4P PRODUCTION BY BYSTANDER CELLS: A POTENTIAL
MECHANISM TO CONTROL T-CELL RESPONSES IN THE LOCAL
MICROENVIRONMENT
How can the evidence obtained using exogenously added
GroPIns4P be related to the physiological context of T-cell traffick-
ing? Measurements of the GPI levels in Jurkat T-cells using a quan-
titative mass spectrometry approach revealed that these cells are
among those with the lowest intracellular levels of GroPIns (15).
At variance with T-cells, macrophages produce large amounts of
GPIs in response to pro-inflammatory stimuli (2, 5), generating a
gradient for their transporter-mediated release into the extracellu-
lar medium (2, 15, 42). We propose that these macrophage-derived
GPIs may act as paracrine factors for lymphocytes. In this scenario,
GPIs produced at the site of infection would enhance effector T-cell
recruitment, and thereby contribute to bacterial clearance. Inter-
estingly, among the highest GPI producers are certain tumor cells
(2, 43). The release of these metabolites, combined with chemotac-
tic signals provided by the tumor microenvironment (44), could
be hypothesized to promote T-cell infiltration and activation of
anti-tumor immunity.
GPIs AND T-CELL FATE: A WORKING HYPOTHESIS
By promoting the activation of Lck, exogenous administration
of GroPIns4P to T-lymphocytes triggers a Rho-family dependent
pathway that is integrated with chemokine receptor signaling to
potentiate T-cell chemotaxis (16). Given the central role of Lck
as the initiator kinase in TCR signaling (37), it can be hypothe-
sized that GroPIns4P has the ability to modulate T-cell activation.
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Lck has also been implicated in the regulation of T-cell apoptosis
induced by a wide range of stimuli, including prolonged TCR stim-
ulation (45) and treatment with sphingosine (46), and it is also an
essential component of the signaling pathways that control Ca2+-
mediated T-cell apoptosis, which involve both the conformational
activation of Bax and the expression of proapoptotic Bcl-2 fam-
ily members (47). How TCR engagement can lead to cell fates as
diverse as activation, anergy, and apoptosis is one of the funda-
mental and as yet open questions in immunology. Investigating
the effects of GroPIns4P, as well as of the other GPIs, on these
processes, may provide valuable information on how TCR signal-
ing is fine-tuned by these phosphoinositide metabolites to elicit
different biological outcomes.
CONCLUSION
The interesting scenarios opened by the studies outlined in this
review using exogenously added GPIs underscore the need to
address the physiological function of endogenous GPIs in the
modulation of immune cell function. It has however to be under-
lined that the results summarized in the present review, while
in part validated on normal peripheral T-cells, have been largely
obtained by exogenous administration of GroPIns4P to Jurkat T-
cells, which are known to be defective in the activity of enzymes
critically involved in lipid signaling, such as PTEN (48). We have
therefore to take into account a possible impact of this defect
on global lipid signaling, which might also involve GPI metabo-
lism. Since, among immune cells, the major producers of GPIs
are macrophages, it will be interesting to assess the impact of
this physiological source of exogenous GPIs on normal T-cells in
co-culture experiments. Unfortunately the study of immune mod-
ulation by GPIs in vivo, which in principle could be approached
using PLA2IVα−/−mice, is prevented by lack of effect of PLA2IVα
deficiency on GPI synthesis, at least in this model. This finding
is likely to be accounted for by the fact that in PLA2IVα−/−
cells GPI synthesis is taken over by the calcium-independent
PLA2VI, suggesting that a compensatory mechanism is activated
under these conditions (15). A way to circumvent this problem
in the future could be to generate an inducible knockout mouse
lacking PLA2IVα expression in macrophages and/or T-cells, or
alternatively to modulate the expression of the specific GDEs.
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